The epothilones: Translating from the laboratory to the clinic

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1618-1624

  Lee, James J ^a   Swain, Sandra M ^b  

^a YALE CANCER CENTER   (United States)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BMS 310705; EPOTHILONE A; EPOTHILONE B; EPOTHILONE C; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; KOS 1584; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CLINICAL TRIAL; DRUG MECHANISM; DRUG MONITORING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROGNOSIS;

EID: 41549164459     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-2201     Document Type: Review

References (94)

1. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot Tokyo 1996;49:560-3.
2. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
3. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32:S22-6.
4. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
5. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32:S3-8.
6. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
7. Bhandari MS, Hussain M. Epothilones and the next generation of phase III trials for prostate cancer. BJU Int 2005;96:296-302.
8. Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006;32:166-79.
9. Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006;15:691-702.
10. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80.
11. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
12. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 1995;55:2325-33.
13. Bode CJ, Gupta ML, Jr., Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-4.
14. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on ah-tubulin by electron crystallography. Science 2004;305:866-9.
15. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003;63:6026-31.
16. Chen JG, Horwitz SB. Differentialmitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;62:1935-8.
17. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and metaanalysis. Semin Oncol 2005;32:S9-15.
18. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
19. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997;272:2534-41.
20. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002;8:2035-43.
21. Kelley MJ, Li S, Harpole DH. Genetic analysis of the h-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:1886-8.
22. Sale S, Oefner PJ, Sikic BI. Re: genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2002;94:776-7; author reply 7.
23. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000;97:2904-9.
24. He L, Yang CP, Horwitz SB. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001;1:3-10.
25. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res 2003;63:1207-13.
26. Chou TC, Zhang XG, Balog A, et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A1998;95:9642-7.
27. Altmann KH, Pfeiffer B, Arseniyadis S, Pratt BA, Nicolaou KC. The chemistry and biology of epothilones-the wheel keeps turning. Chem Med Chem 2007;2:396-423.
28. Chou TC, Zhang XG, Harris CR, et al. Desoxyepothilone Bis curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A 1998;95:15798-802.
29. Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother Pharmacol 2005;56:145-53.
30. Mekhail T, Chung C, Holden S, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21days. Proc Am Soc Clin Oncol 2003;22:Abstr 515.
31. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942-8.
32. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
33. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone b analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
34. Perez EA, Lerzo G, Pivot X, et al. Efficacyand safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
35. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
36. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
37. Vahdat LT, Thomas E, Li R, et al. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. Proc Am Soc Clin Oncol 2007;25:Abstr 1006.
38. Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25:63-7.
39. Lee JJ, Low JA, Croarkin E, et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006;24:2084-91.
40. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol 2006;24:1633-42.
41. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 2007;25:3389-91.
42. Puglisi F, Andreetta C, Valent F, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 2007;18:883 -8.
43. Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. Proc Am Soc Clin Oncol 2006;24:Abstr 12017.
44. Thomas E, Bunnell CA, Vahdat LT, et al. A phase I study of BMS-247550 in combination with capecitabine in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. Breast Cancer Res Treat Suppl 2003:Abstr 350.
45. Zhou Y, Lin J, Johnson RG, Jr. KOS-862 (epothilone D) and 5′-deoxy-5-fluorouridine or 5-fluorouracil in human breast cancer cells: marked synergistic antitumor effects and induction of thymidine phosphorylase expression. Proc Am Assoc Cancer Res 2004;45:Abstr 5429.
46. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
47. Vansteenkiste J, Lara PN, Jr., Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55.
48. Hussain M, Tangen CM, Lara PN, Jr., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormonerefractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
49. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
50. Zhuang SH, Menefee M, Kotz H, et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Proc Am Soc Clin Oncol 2004;22:Abstr 4550.
51. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 2007;110:759-63.
52. Ajani JA, Safran H, Bokemeyer C, et al. A multicenter phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006;24:441-6.
53. Whitehead RP, McCoy S, Rivkin SE, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515-20.
54. Singh DA, Kindler HL, Eng C, et al. Phase II trial of the epothilone Banalog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol 2003;22:Abstr 1127.
55. Okuno S, Maples WJ, Mahoney MR, et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 2005;23:3069-73.
56. Eng C, Kindler HL, Nattam S, et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004;15:928-32.
57. Pavlick AC, Millward M, Farrell K, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). Proc Am Soc Clin Oncol 2004;22:Abstr 7542.
58. Anderson S, Dizon D, Sabbatini P, et al. Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol 2004:Abstr 2098.
59. Plummer R, Molife R, Verrill M, et al. Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2002:Abstr 2125.
60. Chuang E, Vahdat L, Caputo T, et al. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cancers: New York Cancer Consortium Trial P7229. Proc Am Soc Clin Oncol 2007;Abstr 2570.
61. Hussain A, Dipaola RS, Baron AD, et al. A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC). Proc Am Soc Clin Oncol 2004;22:Abstr 4563.
62. Venook AP, Poon R, Kang YK, et al. Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2007;25:Abstr 15055.
63. Hsin KW, Boyer M, Ducreux M, et al. Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Proc Am Soc Clin Oncol 2006;24:Abstr 4069.
64. Sánchez JM, Mellemgaard A, Perry M, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): A phase I/II trial. Proc Am Soc Clin Oncol 2006;24:Abstr 7104.
65. Poplin E, Moore M, O'Dwyer P, et al. Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 phase II trials. Proc Am Soc Clin Oncol 2003:Abstr 1135.
66. Smit WM, Sufliarsky J, Spanik S, et al. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. Proc Am Soc Clin Oncol 2005;23:Abstr 5056.
67. Thompson JA, Swerdloff J, Escudier B, et al. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol 2003:Abstr 1628.
68. Anthony LB, Carlisle T, Pommier R, Benson A, Rafferty T, Rothermel J. An open-label phase IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors. Proc Am Soc Clin Oncol 2003:Abstr 1413.
69. Overmoyer B, Waintraub S, Kaufman PA, et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:Abstr 778.
70. Yee L, Lynch T, Villalona-Calero M, et al. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. Proc Am Soc Clin Oncol 2005;23:Abstr 7127.
71. Rustin GJ, Reed NS, Jayson G, et al. Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 2007;25:Abstr 5527.
72. Sessa C, Perotti A, Malossi A, et al. Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol 2003:Abstr 519.
73. Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082 -8.
74. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
75. Mani S, McDaid HM, Grossman A, et al. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol 2007;18:190-5.
76. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
77. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003;4:938-47.
78. Zhuang SH, Hung YE, Hung L, et al. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res 2007;13:7480-6.
79. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996;84:623-31.
80. Chapin SJ, Lue CM, Yu MT, Bulinski JC. Differential expression of alternatively spliced forms of MAP4: a repertoire of structurally different microtubule-binding domains. Biochemistry 1995;34:2289-301.
81. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007;71:1233-40.
82. Samsonov A, Yu JZ, Rasenick M, Popov SV. Tau interaction with microtubules in vivo. J Cell Sci 2004;117:6129 -41.
83. Ross JL, Santangelo CD, Makrides V, Fygenson DK. Tau induces cooperative Taxol binding to microtubules. Proc Natl Acad Sci U S A 2004;101:12910-5.
84. Gown AM, Goldstein LC, Porter PL, et al. Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. Proc Am Soc Clin Oncol 2006;24:Abstr 543.
85. Andre F, Hatzis C, Anderson K, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-7.
86. Lee H, Xu L, Wu S, et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. Proc Am Soc Clin Oncol 2006;24:Abstr 3011.
87. Wu S, Chasalow S, Lee H, et al. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients. Proc Am Soc Clin Oncol 2007;25:Abstr 2525.
88. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1650-57.
89. Choy H, Park C, Yao M. Current status and future prospect for satraplatin: an oral platinum analogue. Clin Cancer Res 2008;14:1618-23.
90. Orlowski RZ and Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1634-43.
91. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1624-33.
92. Bennouna J, Delord JP, Campone M, Pinel M. Vinflunine: a newmicrotubule inhibitor agent. Clin Cancer Res 2008;14:1610-17.
93. Yang CP, Verdier-Pinard P, Wang F, et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 2005;4:987-95.
94. Verrills NM, Flemming CL, Liu M, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003;10:597-607.